Dr Reddy’s US drug pricing comes under scrutiny

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Dr Reddy’s US drug pricing comes under scrutiny

Generics/General | Posted 03/04/2015 0 Post your comment

Dr Reddy’s Laboratories, the India-based generics drugmaker, has been asked to share drug-pricing information with the attorneys general of California and Texas in November 2014. The two US States take their lead from an investigation into generics pricing at the national level.

US Federal law currently requires branded drugmakers, but not generic drugmakers, to pay a rebate when their prices rise above inflation levels. Congress launched an investigation in November 2014 into recent price increases for generic drugs. A separate Department of Justice inquiry is also underway into price increases for generic drugs.

Independent Bernie Sanders in the Senate and Democrat Elijah Cummings in the House said when the investigation was launched that extending the existing law to cover generic drugmakers, through the Medicaid Generic Drug Fairness Act, would save US taxpayers US$500 million over 10 years. Cummings and Sanders wrote to Dr Reddy’s in 2014, requesting pricing information for drugs including the migraine treatment Divalproex Sodium ER, the price of which had increased by 736% between October 2013 and April 2014.

The Generic Pharmaceutical Association (GPhA), which represents generic drugs companies, says the inquiries are focussing too narrowly on just a few price hikes.

‘Generic drugs continue to be a resounding success in lowering healthcare costs and benefiting patients,’ said GPhA president, Mr Ralph Neas, in a statement from the association. ‘Indeed, generics saved US$239 billion in 2013 (a 14% increase in savings from 2012) and more than US$1.46 trillion over the recent decade.’

Generic antiepileptic drugs bioequivalent to brand-name drugs

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.